Business Blockbuster - Helpng business to be more visible on Google

Daily Bulletin

Racura Oncology's RC220 Matches RC110 Drug Exposure in Nonclinical Bridging Study, Linking RC220 to Prior Clinical Experience in AML

  • Written by: Daily Bulletin

Exposure ratios met pre-specified equivalence criteria on all three dosing days, supporting use of the established RC110 clinical dataset and dosing levels for RC220, including in the Phase 2b/3 EMILI trial in

acute myeloid leukemia

SYDNEY, Nov. 17, 2026 /PRNewswire/ -- Racura Oncology Ltd (ASX: RAC) ("Racura" or the "Company"), a late clinical-stage biopharmaceutical company developing new small molecule-based approaches to cancer treatment focused on inhibiting MYC gene expression, today announced results from a Good Laboratory Practice (GLP) nonclinical pharmacokinetic (PK) bridging study showing that RC220, the Company's proprietary formulation of (E,E)-bisantrene, delivers systemic drug exposure equivalent to RC110, the earlier formulation used in two investigator-sponsored clinical trials in relapsed or refractory (R/R) acute myeloid leukemia (AML).

In the study, conducted in Beagle dogs (n = 6), the 90% confidence intervals (CIs) of the geometric mean ratios (GMRs) of RC220 to RC110 exposure for both peak plasma concentration (Cmax) and total exposure (area under the concentration–time curve, AUC) fell within the pre-specified equivalence range of 0.80–1.25 on each of three consecutive dosing days, with GMRs ranging from 0.971 to 1.057. These nonclinical data support applying the established RC110 clinical dataset and dosing levels to the clinical development of RC220, including the Phase 2b/3 EMILI trial in AML.

Daniel Tillett, Ph.D., Chief Executive Officer of Racura Oncology, said: "This nonclinical study was designed to answer a critical question for our RC220 clinical programs: does RC220 deliver the same drug exposure as RC110? The results of this GLP PK study show the two formulations delivered equivalent exposure to (E,E)-bisantrene. The findings provide an important bridge to the clinical experience with RC110, which produced a 40% response rate in two separate clinical trials in heavily pretreated AML patients. The bridging study results support our plans to evaluate RC220 in patients with AML in the EMILI trial as well as our HARNESS and CPACS clinical programs. I wish to thank the Racura team and our study partners for the careful execution of this important work."

Study Design and Results

RC110 and RC220 contain the same active ingredient, (E,E)-bisantrene, and differ only in their formulation excipients. RC220 was developed to allow (E,E)-bisantrene to be given through a peripheral vein, rather than requiring a central venous line.

The study used a two-period crossover design in which each male Beagle dog received once-daily intravenous doses (30-minute infusion) of RC110 and RC220 for three consecutive days, in random order and separated by a five-day washout, so that each animal served as its own control. Repeat daily dosing was examined because RC110 was given as a daily infusion over several consecutive days in the earlier AML trials, and the same approach is planned for RC220.

Equivalence was assessed using the statistical approach described in US Food and Drug Administration (FDA) and European Medicines Agency (EMA) bioequivalence guidance, in which the 90% CI of the GMR must lie entirely within 0.80–1.25. All six intervals met this criterion, with the widest being 0.841–1.179 for Day 1 Cmax (Figure 1).

Figure 1. RC220 and RC110 deliver equivalent exposure to (E,E)-bisantrene with repeat daily dosing. (A) Geometric mean peak plasma concentration (Cmax) of (E,E)-bisantrene after each of three once-daily intravenous doses (30-minute infusion) of RC110 or RC220 in male Beagle dogs (n = 6, two-period crossover with a five-day washout). (B) Ratio of RC220 to RC110 exposure (geometric mean ratio with 90% confidence interval) for Cmax and AUC on each dosing day. The shaded band is the pre-specified equivalence range of 0.80–1.25; a ratio of 1.00 indicates identical exposure.
Figure 1. RC220 and RC110 deliver equivalent exposure to (E,E)-bisantrene with repeat daily dosing. (A) Geometric mean peak plasma concentration (Cmax) of (E,E)-bisantrene after each of three once-daily intravenous doses (30-minute infusion) of RC110 or RC220 in male Beagle dogs (n = 6, two-period crossover with a five-day washout). (B) Ratio of RC220 to RC110 exposure (geometric mean ratio with 90% confidence interval) for Cmax and AUC on each dosing day. The shaded band is the pre-specified equivalence range of 0.80–1.25; a ratio of 1.00 indicates identical exposure.

The dog is a standard species for nonclinical PK and safety studies and was one of the two species used in the GLP toxicology program for RC220. The doses used were well below the level that causes harm, and no animal was harmed in the study. These results characterize drug exposure in the bloodstream of dogs; they do not measure anticancer activity. The safety and efficacy of RC220 in patients with AML remain to be established in clinical trials.

Significance for the RC220 Clinical Programs

RC110 was used in two investigator-sponsored clinical trials in R/R AML conducted at Sheba Medical Center, Israel. In a Phase 2 trial, RC110 given as a single agent produced an overall response rate (complete or partial responses) of 40% in 10 patients (Canaani et al., Eur J Haematol 2021). In a Phase 1b/2 trial, RC110 combined with fludarabine and clofarabine produced a response in 6 of 15 evaluable patients (Danylesko et al., Br J Haematol 2025). These results underpin Racura's plan to advance RC220 in AML through the Phase 2b/3 EMILI trial.

RC220 is already being administered to patients through a peripheral vein in the Phase 1 CPACS solid tumor trial and the Phase 1 HARNESS lung cancer trial. While the bridging study results are not essential for these trials, they may help accelerate dose escalation or progression to later-stage trials. Racura will use the results to support regulatory submissions for AML and other clinical indications.

About RC220 & (E,E)-bisantrene

RC220 is a proprietary formulation of (E,E)-bisantrene designed to overcome drug solubility issues that prevent safe peripheral intravenous infusion. (E,E)-bisantrene is a clinically validated small molecule anticancer agent that primarily functions via G4-DNA and RNA binding, leading to potent transcriptional inhibition of the important cancer growth regulator MYC and downstream pathways.

About Racura Oncology

Racura Oncology (ASX: RAC) is a late clinical-stage biopharmaceutical company with a mission to silence cancer. Our lead asset, (E,E)-bisantrene, is a small molecule anticancer agent that primarily functions via G4-DNA and RNA binding, leading to potent transcriptional inhibition of the important cancer growth regulator MYC. G4-binding by (E,E)-bisantrene has additional anticancer activities including inhibition of topoisomerase II and telomerase, as well as m6A RNA pathway modulation.

Racura is advancing RC220 to address the high unmet needs of patients across multiple oncology indications, including the EMILI Phase 2b/3 trial in acute myeloid leukemia (AML), the HARNESS Phase 1 trial in combination with osimertinib in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and the CPACS Phase 1 trial in combination with the anthracycline doxorubicin, where we aim to deliver both cardioprotection and enhanced anticancer activity for solid tumor patients.

Learn more at www.racuraoncology.com.

Forward-Looking Statements

Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this release include, without limitation, statements regarding expectations regarding clinical development and regulatory strategy and the Company's ability to deliver meaningful value to patients and shareholders. These statements relate to future events, future expectations, plans and prospects. Although Racura believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Racura has attempted to identify forward-looking statements by terminology including "believes", "estimates", "anticipates", "expects", "plans", "projects", "intends", "potential", "may", "could", "might", "will", "should", "approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including market and other conditions. Any forward-looking statements contained in this press release speak only as of its date. Racura undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except as required by law.

Business News

The Growing Demand for Durable Plastic Packaging Supplies Across Australia

Why Do Australian Businesses Need Reliable Plastic Packaging Supplies? Businesses need packaging that can withstand everyday handling, storage, and distribution without creating avoidable delays. Pla...

Daily Bulletin - avatar Daily Bulletin

Office Cleaning Melbourne: Choosing the Right Scope for Your Office

A well-planned office cleaning Melbourne arrangement starts with a clear understanding of the premises and the people who use it. An office may include private work areas, shared desks, reception, mee...

Daily Bulletin - avatar Daily Bulletin

How Businesses Can Prepare for Unexpected Power Outages

Power failures can occur quickly. The supply may be interrupted by bad weather, issues with the electricity network, damaged equipment or local construction work. This can be just a hassle for a fam...

Daily Bulletin - avatar Daily Bulletin

How Chatswood Tutoring Can Fit Into a Student’s Weekly Routine

Create a Predictable Weekly Structure A consistent weekly routine can make study easier to manage when students are balancing several subjects. Chatswood tutoring can provide a fixed learning point a...

Daily Bulletin - avatar Daily Bulletin

The Rise of Digital Marketplaces in the Australian Trade Sector

For decades, the Australian trade and construction sector operated almost entirely on word-of-mouth recommendations and local community networks. Small business owners typically relied on local newspa...

Daily Bulletin - avatar Daily Bulletin

How Immigration Lawyers Can Help

Introduction Visa decisions can shape employment, family life, study plans, travel, and future residence. A small omission can lead to delay, added expense, or refusal. Immigration lawyers assess l...

Daily Bulletin - avatar Daily Bulletin

How Industrial Drying Equipment Supports Efficient Processing

Many industrial processes require moisture to be removed from compressed air, products or process materials before they move to the next stage. Excess moisture can affect equipment performance, produc...

Daily Bulletin - avatar Daily Bulletin

Practical Ways a Whiteboard Can Improve Workplace Communication

Effective communication helps teams stay organised, share ideas and keep track of important information. While digital tools are now common in many workplaces, a whiteboard continues to provide a simp...

Daily Bulletin - avatar Daily Bulletin

Designing Eco-Friendly Custom Water Bottles for Your Next Event

The Evolution of Sustainable Event Merchandise Event planning has undergone a massive transformation over the last decade. Gone are the days when organizers could hand out cheap, single use plastic...

Daily Bulletin - avatar Daily Bulletin

The Daily Magazine

Work Boots vs Safety Shoes: Which Footwear Is Right for Your Workplace?

Not every job calls for a heavy pair of boots. Walk through a modern warehouse, factory floor or dis...

Master Bedroom Wall Decor Guide: Sizing, Layouts and Styling Ideas for Every Space

The main bedroom is often the last room in the house to get any attention. The living room gets the ...

What to Consider Before Installing a Built-In Wardrobe

Living in a modest home teaches you a lot. You learn how to keep a small kitchen tidy, where to hi...

Top 5 Mortgage Brokers in Sydney: How to Choose the Right One in 2027

Finding a mortgage broker in Sydney is not particularly difficult. Finding one who understands your ...

How Much Life Does Your Roof Have Left? Recognizing When Replacement Becomes Necessary

A roof can age quietly for years. From the street, everything may look reassuringly ordinary, even w...

How Australian Drivers Can Make Their Cars Harder to Steal

Most people don't think much about car theft until it happens to them, or to someone they know. Th...

The Short-Term Rental Rules Australian Owners Can’t Afford to Guess At

A holiday let looks simple from the outside: a spare property, a listing, some guests. Underneath ...

The Risks Of Removing Ear Wax Without Professional Guidance

Ear wax is an essential component of the hygiene process since it acts as a barrier between the ea...

Plumbing Call-Out Fees in Perth Explained

When you hire a plumber to fix a problem with a dripping tap, leaking pipe, or whatever it might be...